UK Authorises Eli Lilly's Once Daily GLP-1 Pill

Second oral GLP-1 authorised for weight loss in the UK in two months, in a private-only market where MedPal's New Health clinic is already operating

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, notes the announcement by the Medicines and Healthcare products Regulatory Agency (MHRA) on 10 August 2026 that the UK has become the first country in Europe to authorise orforglipron (brand name Foundayo), Eli Lilly's once daily oral GLP-1 tablet.

Orforglipron is authorised for weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI of between 27 and 30 with at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased physical activity. The authorisation also extends to improving glycaemic control in patients whose type 2 diabetes is insufficiently controlled.

Highlights

• The UK's second oral GLP-1 weight loss authorisation in two months. Orforglipron follows the MHRA's approval of Novo Nordisk's oral semaglutide tablet in June 2026. Two of the world's largest pharmaceutical companies now have once daily weight loss pills authorised in the UK, and the UK is the first country in Europe for both.
• Private-only access at launch. Foundayo is not currently available on the NHS and remains subject to evaluation by the National Institute for Health and Care Excellence (NICE). Private provision, the market in which the Group's dedicated GLP-1 clinic New Health (new.co.uk) operates, is presently the only route to access.
• New Health is already scaling in this market. As announced on 4 August 2026, New Health generated over £180,000 of private prescription revenue in July 2026 from only three weeks of marketing, an annualised run rate of over £2.2 million, within a Group annualised recurring revenue run rate of approximately £8.6 million.
• MedPal is an approved Eli Lilly purchaser. MedPal Limited, the Company's wholly owned subsidiary, was approved as an authorised purchaser of Eli Lilly pharmaceutical products in the UK in January 2026, and the Group has direct supply agreements with both Eli Lilly and Novo Nordisk for current GLP-1 medicines.
• Oral formats appear to be expanding the market, not splitting it. As reported in the Company's announcement of 12 June 2026, more than 80 per cent of new prescriptions for the first oral GLP-1 in the US were for patients new to GLP-1 therapy. The Board believes each new oral option brings further first-time patients into the category that New Health was built to serve.

Eli Lilly has indicated that Foundayo is expected to launch in the UK later this month via private prescription but pricing has not yet been announced.. The Company will provide a further update as appropriate.

Chief Executive Officer's Commentary

Jason Drummond, Founder and Chief Executive Officer of MedPal, commented:

"Two once daily oral GLP-1 pills for weight management authorised in the UK inside two months, and in both cases the UK is first in Europe. The direction of travel is unmistakable: the GLP-1 market is expanding to include convenient oral treatments that bring in patients who would never have started with an injection, and for now the only way to access them is privately.

"That is exactly the market New Health was built for, and it is already delivering: over £2.2 million of annualised revenue after just three weeks of marketing. With clinician-led prescribing, robotic dispensing and an approved purchasing relationship with Eli Lilly in place, every new authorisation potentially widens our customer funnel."

The Directors of the Company are responsible for the contents of this announcement.